Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Accenture
Baxter
Julphar
UBS
Harvard Business School

Generated: July 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,536,150

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,536,150 protect, and when does it expire?

Patent 8,536,150 protects LEXISCAN and is included in one NDA.

This patent has four patent family members in three countries.

Summary for Patent: 8,536,150
Title:Methods of myocardial perfusion imaging
Abstract: The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.
Inventor(s): Belardinelli; Luiz (Palo Alto, CA), Blackburn; Brent K. (Los Altos, CA), Gao; Zhenhai (San Jose, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:13/525,223
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,536,150
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,536,150

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF MYOCARDIAL IMAGING ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Teva
Julphar
Merck
Argus Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.